VHH Antibody Discovery
Custom VHH Antibody discovery, delivered with speed, precision, and partnership – powered by the world’s largest synthetic VHH libraries and proprietary CIS Display™ technology.
Antibody discovery - Fast, Customised and Built for Scientists
At Isogenica, we work as a specialized extension of your team – open, agile, and grounded in science. From high-throughput screening to custom VHH engineering, our approach accelerates timelines, strengthens IP, and reduces early-stage risk. Whether you’re targeting a tough indication or racing to a milestone, we help you reach inflection points with clarity and confidence. Precision. Partnerships. Progress. That’s the Isogenica difference.
Trusted by Leading Biotech Innovators
From emerging biotechs to established pharma leaders, our partners rely on our speed, scale, and science
What You Can Expect from Isogenica
Faster Discovery, Stronger Candidates
The World’s Biggest Synthetic VHH Libraries
The world’s largest synthetic VHH libraries deliver 100–1000× more screening to achieve higher-affinity hits. Proprietary screening technology scales discovery even further, deepening datasets and leading to faster timelines and stronger candidate profiles.
Built for Scientists. Backed by Cambridge.
Driven by Discovery. Trusted for Results.
From the start, Isogenica offered thoughtful input and multiple strategic proposals to help us design the most effective path to the VHHs we were aiming for. We’ve genuinely valued their partnership.
Thibault Harmand, Ph.D., Acting CEO of Cerberus Therapeutics
VHH Resources
Explore our VHH resources – including white papers, blog posts and webinars
The Proteins We Work With: A Guide to Supported Antigen Materials
A technical overview of how in vitro discovery platforms support VHH antibody and peptide discovery across challenging protein classes, from soluble enzymes to membrane proteins, toxic antigens and complex multimeric targets, using tailored antigen presentation strategies. Read more
Upcoming Events
Check out our upcoming events and see where we’ve been recently.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Latest Webinars
Watch expert-led webinars on VHH discovery, difficult targets and therapeutics.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Explore the science behind our antibody discovery platforms
White Paper “Data-Driven Validation of Synthetic VHHs”
This white paper provides a data-driven validation of Isogenica’s synthetic VHH libraries, powered by Colibra® technology. Designed for biotech and pharmaceutical scientists, it demonstrates how these libraries enhance and accelerate drug discovery, particularly in oncology and immunotherapy. Download Extending half-lives of VHH antibodies
Because VHHs are small, they can be cleared quickly from the bloodstream. This can be a useful feature for some applications, but often a longer plasma half-life is desirable. DOWNLOADAdvantages of VHH in bi-specifics
To learn more about the application of VHHs in bi-specifics, we have condensed our expertise into a downloadable Application Note. DOWNLOADOptimizing CAR-T and T-cell antibody engagers: a role for VHH single domain antibodies
This whitepaper summarises the clinical and research landscape for CAR-T and T-cell engaging antibody therapies and show how single domain VHH antibodies can be applied to optimise the next generation of these important new therapeutic modalities. DOWNLOADIsogenica’s PD-L1 VHH as Functional Antagonists
PD-1 is an immune checkpoint protein expressed on the surface of multiple types of immune cells, including antigen-stimulated T-cells and tumour specific T-cells1. Interaction between PD-1 and its ligands (PD-L1 or PD-L2), is responsible for the regulation of T-cell activation, apoptosis, proliferation and cytokine production. DOWNLOADAnti-LRP5/6 VHH inhibits WNT pathway and prevents tumour growth
VHH are the variable domain of heavy chain only antibodies. They are small in size (~15 kD) and biophysically robust. With tunable half-lives, these antibodies are ideal for targeting inaccessible epitopes, achieving enhanced tissue penetration, multi-target binding and formatting for payload delivery… DOWNLOAD